Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial : Episode 4
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
- What is your standard of care (SOC) in this patient population?
- How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025Podcast
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Viviana Cortlana, MS4;Jade Gambill, BSc;Jenna Ghazal, BSc;Kennedy Itodo;Shreevikaa Kannan, PGY-5;Yan Leyfman, MD;Chandler H. Park, MD, FACP
March 7th 2025Article
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
